Investing analyses

# TVTX — Earnings Review Q4 FY25 (Atlas)

> Date: 2026-04-03
> Quarter: Q4 FY25 (Dec 31, 2025; reported Feb 19, 2026)
> Market cap: $2.81B | EV/TTM Rev: 5.7x | Revenue growth: 73.4% YoY (Q4); 110.3% YoY (FY25)
> Stock price: ~$30.93 (Apr 3, 2026) | Shares: 90.9M diluted

## Verdict

FILSPARI's commercial trajectory is exceptional and accelerating at the demand level — record 908 PSFs in Q4 (+24% QoQ), $103.3M product revenue (first $100M+ quarter), and annual OCF turning positive for the first time in company history. The headline revenue "miss" of -$18M vs consensus is a license revenue timing artifact, not a fundamental signal. With FSGS PDUFA 10 days away (April 13), this is a company where the underlying product engine is firing on all cylinders while the stock trades at 5.7x trailing revenue on 110% growth. Conviction: **4/5** — unchanged from stock analysis. The FSGS binary and A/R divergence prevent maximum conviction.

## Qualification Gate

| Criterion | Threshold | Actual | Status |
|-----------|-----------|--------|--------|
| Revenue YoY growth | >30% | +73.4% Q4; +110.3% FY25 | **PASS** |
| Gross margin | >60% | 98.0% (GAAP) | **PASS** |
| Revenue per quarter | >$50M | $129.7M | **PASS** |
| Data availability | 4+ quarters | 16 quarters | **PASS** |
| Share dilution | <10% annual | ~8.7% (83.1M to 90.3M) | **PASS** |
| GAAP profitability trajectory | Improving or positive | FY25 loss -$25.5M vs -$321.5M; first OCF-positive year | **PASS** |

All gates passed.

## Six-Factor Score

| Factor | Rating | Detail |
|--------|--------|--------|
| Growth | **Strong** | FY25 +110.3% YoY ($490.7M); FILSPARI +144% ($322M); Q4 FILSPARI +108% YoY ($103.3M). Core product growth obscured by $80.3M in FY25 license revenue that won't recur. |
| Trajectory | **Accelerating (annual) / Decelerating (quarterly)** | FY23 +33% -> FY24 +60% -> FY25 +110% at annual level. Quarterly YoY: 97% -> 112% -> 162% -> 73%. Q3 peak was license-inflated; Q4 decline is normalization. FILSP

*…truncated*

# TVTX — Stock Analysis

**FILSPARI is a generational drug launch hiding behind a binary catalyst.** This company did $490.7M in FY25 revenue (+110% YoY), hit positive operating cash flow for the first time ($37.8M), achieved Non-GAAP profitability ($0.91 EPS), and is adding patients at an all-time high rate — all while trading at 5.3x run-rate P/S. The PEG of 0.048 is absurd. But the FSGS PDUFA on April 13 (11 days out) is the elephant in the room: the DUPLEX trial **missed its primary eGFR endpoint**, and the market is pricing that binary risk. I think the expected value is positive, but this is not a clean setup. Let me walk through the numbers.

> Date: 2026-04-02
> Market cap: ~$2.76B ($30.39 × 90.9M shares)
> FY ends: December (calendar year)
> Run-rate revenue: $518.8M (Q4 × 4)
> Run-rate P/S: 5.3x
> 52-week range: $12.91–$42.13

---

## The Numbers

### Revenue Grid — Total ($M)

| | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| **Q1** | 23.4 | 30.9 | 41.4 | 81.7 |
| **Q2** | 28.6 | 32.2 | 54.1 | 114.4 |
| **Q3** | 28.1 | 37.1 | 62.9 | 164.9* |
| **Q4** | 29.3 | 45.1 | 74.8 | 129.7 |
| **Full Year** | 109.4 | 145.3 | 233.2 | 490.7 |
| **YoY %** | — | +32.7% | +60.3% | **+110.3%** |

*Q3 FY25 inflated by $51.7M CSL Vifor license milestone. Net product sales were $113.2M.

→ Annual revenue growth is **accelerating**: 32.7% → 60.3% → 110.3%. This is a drug-launch S-curve, and it's textbook beautiful at scale.

### FILSPARI Revenue Grid — The Only Number That Matters ($M)

| | FY24 | FY25 |
|---|---|---|
| **Q1** | 19.8 | 55.9 |
| **Q2** | 27.1 | 71.9 |
| **Q3** | 35.6 | 90.9 |
| **Q4** | 49.6 | 103.3 |
| **Full Year** | 132.2 | **322.0** |
| **YoY %** | — | **+144%** |

FILSPARI quarterly YoY: Q1 +182% → Q2 +165% → Q3 +155% → Q4 +108%. Decelerating on base effects — expected and not a red flag when the annual number is +144%.

### FILSPARI QoQ — Where I'm Watching Closely

| Quarter | FY24 QoQ | FY25 QoQ |
|---|---|---|
| **Q1** | — | +13% |
| **Q2** | +3

*…truncated*

# TVTX — Stock Analysis (Phil Fisher)

> Date: 2026-04-06
> FY ends: December (calendar year)
> Market cap: ~$2.8B | P/S (TTM): 5.7x | Revenue growth: 110.3% YoY (FY25)
> Shares outstanding: 90.9M
> FSGS PDUFA: April 13, 2026 (7 days from this analysis)

---

## Verdict

I believe Travere Therapeutics is a genuinely outstanding company at a rare inflection point — the transition from a money-losing specialty pharmaceutical concern into a profitable, growing franchise built around a first-in-class kidney drug. In my experience, these transitions are among the most rewarding moments for the patient, long-term investor who has done his homework.

FILSPARI is not merely "fortunate" — it is fortunate because it is able. Management did not stumble into a blockbuster; Eric Dube inherited a troubled company called Retrophin in 2019, rebranded it, refocused its pipeline on rare kidney disease, secured FDA approval, then drove $322 million in FILSPARI sales in FY25 with fewer than 400 employees. That is the hallmark of management ability creating growth, not riding industry tailwinds.

The company satisfies the large majority of my Fifteen Points. It has outstanding growth potential across multiple indications and geographies, effective research producing real clinical results, a lean and capable sales organization, improving margins on a trajectory toward GAAP profitability, and management that speaks candidly about both opportunities and challenges. The FSGS approval decision on April 13 represents a binary catalyst that could roughly double the addressable market — and the company has already invested in the field force to capture it.

**My verdict: Buy.** This is a company I would want to own for the long term. The valuation at 5.7x trailing revenue on 110% growth is, to use a precise term, cheap. The PEG ratio of 0.05 is among the most attractive I have encountered in decades of investing. I would take a meaningful initial position — 3-5% of a concentrated portfolio — wi

*…truncated*

# TVTX (Travere Therapeutics) — Stock Analysis

> **Date:** April 2, 2026
> **Persona:** GauchoRico
> **Market Cap:** ~$2.76B ($30.39 x 90.9M shares)
> **EV/TTM Revenue:** ~5.6x ($2.75B EV / $490.7M)
> **FY25 Revenue Growth:** +110.3% YoY
> **Stock Price:** ~$30.39 | 52-week range: $12.91-$42.13
> **FSGS PDUFA:** April 13, 2026 (11 days away)

---

## Verdict

Holy smokes -- this is one of the most compelling risk/reward setups I've seen in a long time. Travere is a specialty pharma company that has gone from a chronic cash-burner to an operational inflection point, driven by FILSPARI, a first-in-class kidney drug with 98% gross margins growing at 144% YoY. The company trades at an EV/TTM Revenue of 5.6x on 110% revenue growth -- that's a PEG of 0.05. I can count on one hand the number of times I've seen a PEG that low on a company with this quality of growth.

The kicker: the FSGS PDUFA decision on April 13 could approximately double the addressable market. If approved, FILSPARI would be the first and only drug approved for FSGS -- an uncontested indication. That's the kind of competitive dominance I look for.

But let's be rigorous. The DUPLEX trial **missed its primary eGFR slope endpoint** at 108 weeks, even though it hit the pre-specified interim proteinuria endpoint and showed lower rates of end-stage kidney disease. The FDA classified Travere's additional response as a "Major Amendment" -- not routine. While the AdCom removal is a bullish signal, this is NOT a guaranteed approval. I want to be honest about that binary risk.

**Conviction: 4/5.** If I didn't have the binary FSGS event 11 days out, this would be 5/5 on fundamentals alone. The binary risk keeps it at 4.

---

## The Numbers

### Revenue & Growth (12 Quarters)

```
            Revenue   YoY%      QoQ%     GM%[GAAP]  OpMrg[GAAP]  OpMrg[Non-GAAP]  EPS[GAAP]  EPS[Non-GAAP]
Q1'23       $30.9M    +32.1%    +5.5%    86.7%      -315%        --               -$1.27     --
Q2'23       $32.2M    +12.6%    

*…truncated*

# TVTX — Stock Analysis (Bear)

> Date: 2026-04-02
> FY ends: December (calendar year)
> Market cap: ~$2.81B | P/S (TTM): 5.7x | Revenue growth: 110.3% YoY (FY25)
> Shares outstanding: 90.9M
> Data source: Scout brief 2026-04-01 | Atlas baseline 2026-04-01

## Starting Point: Atlas Baseline

Atlas scored TVTX as a 4/5 conviction play with a PEG of 0.05, calling it "deeply discounted to the growth rate." I largely agree with Atlas's numbers — the financial profile is genuinely impressive. Where I diverge is on the risk weighting. Atlas acknowledges the FSGS binary risk and competitive intensification but ultimately leans into the valuation gap as the dominant signal. I want to stress-test that framing.

The numbers have to match the theory. And in this case, the numbers are excellent — but the theory depends heavily on a single FDA decision 11 days from now.

## What Travere Does

Specialty pharma focused on rare kidney diseases. One commercial drug (FILSPARI/sparsentan) for IgA nephropathy (IgAN), approved February 2023. Legacy product (tiopronin) for cystinosis, declining. Pipeline includes FSGS label expansion (PDUFA April 13, 2026), pegtibatinase for HCU (Phase 3), and post-transplant IgAN study (SPARX). CSL Vifor partnership for ex-US rights generates milestones.

## The Numbers

### Revenue & Growth (8 Quarters)

| Quarter | Revenue ($M) | YoY % | QoQ % | FILSPARI ($M) | FILSPARI QoQ | License ($M) | GM% [GAAP] |
|---------|-------------|-------|-------|--------------|-------------|-------------|-----------|
| Q1 FY24 | 41.4 | 34.0% | -8.2% | 19.8 | — | 1.5 | 96.4% |
| Q2 FY24 | 54.1 | 68.0% | 30.7% | 27.1 | +37% | 1.9 | 96.1% |
| Q3 FY24 | 62.9 | 69.5% | 16.3% | 35.6 | +31% | 1.9 | 97.5% |
| Q4 FY24 | 74.8 | 65.9% | 18.9% | 49.6 | +39% | 1.3 | 96.5% |
| Q1 FY25 | 81.7 | 97.3% | 9.2% | 55.9 | +13% | 5.9 | 94.2% |
| Q2 FY25 | 114.4 | 111.5% | 40.0% | 71.9 | +29% | 19.6 | 98.7% |
| Q3 FY25 | 164.9 | 162.2% | 44.1% | 90.9 | +26% | 51.7 | 99.0% |
| Q4 FY25 | 129.7 

*…truncated*

# TVTX — Travere Therapeutics: Stock Analysis

> Date: April 2, 2026
> Stock price: ~$30.39 | Market cap: ~$2.76B | Shares: 90.9M
> FY ends: December (calendar year)
> FY25 Revenue: $490.7M (+110.3% YoY) | FILSPARI FY25: $322.0M (+144% YoY)

## Verdict

Let me tell you, the numbers on this company got my attention in a big way. FILSPARI revenue went from $132M in FY24 to $322M in FY25 — that's 144% growth! And the annualized run-rate from Q4 is now $413M. This is a specialty pharma company with 98% gross margins and revenue accelerating at scale — annual growth went from 33% (FY23) to 60% (FY24) to 110% (FY25). That is such an extraordinary trajectory!

But — and this is important — there's a binary FDA event on April 13 that could move the stock 30-40% in either direction. The FSGS approval decision is 11 days away. If approved, FILSPARI becomes the first and only drug for FSGS and the addressable market roughly doubles. If rejected, the company still has a strong IgAN franchise but the growth trajectory changes dramatically.

I'm extremely interested in this company. The numbers are among the best I've seen outside of tech/SaaS. But I have to be honest — I'm not a biotech expert, and binary FDA events make me uncomfortable. I'd want a starter position here, with the intention to add significantly if FSGS is approved and the launch goes well. **Conviction: Medium-High.** The numbers are screaming "buy," but the binary event in 11 days demands some caution.

## The Numbers — This Is the Analysis

### Revenue & Margins (8 Quarters)

| Quarter | Revenue ($M) | YoY % | QoQ % | GM% [GAAP] | OpM% [GAAP] | OpM% [Non-GAAP] | EPS (Non-GAAP) |
|---------|-------------|-------|-------|-------------|-------------|-----------------|----------------|
| Q1 FY24 | 41.4 | +34.0% | -8.2% | 96.4% | -336% | — | — |
| Q2 FY24 | 54.1 | +68.0% | +30.7% | 96.1% | -125% | — | — |
| Q3 FY24 | 62.9 | +69.5% | +16.3% | 97.5% | -89% | — | — |
| Q4 FY24 | 74.8 | +65.9% | +18.9% | 96.5% | -81% |

*…truncated*

# TVTX — Travere Therapeutics Stock Analysis

**Date:** April 2, 2026
**Analyst:** StockNovice (Joe)
**Task:** Stock Analysis (first coverage)
**Data source:** Scout brief (2026-04-01) + supplementary web research

---

## What Does Travere Actually Do?

Here's how I'm thinking about this one. Travere Therapeutics is a specialty pharma company focused on rare kidney diseases. Their flagship drug is FILSPARI (sparsentan), which treats IgA Nephropathy (IgAN) — a rare kidney disease where your immune system attacks your kidneys and slowly destroys them. FILSPARI was the first and only non-immunosuppressive therapy approved for IgAN when the FDA gave it the green light in February 2023.

They also sell tiopronin products (for cystinuria, another rare kidney condition), but that's a legacy cash cow — not the growth story.

The big near-term catalyst? They've submitted FILSPARI for a second indication — FSGS (focal segmental glomerulosclerosis) — another rare kidney disease with *zero* FDA-approved treatments. PDUFA date: **April 13, 2026** — eleven days from now.

---

## The Numbers

| Quarter | Revenue ($M) | YoY % | FILSPARI ($M) | FILSPARI YoY | License ($M) | Non-GAAP EPS | Notes |
|---------|-------------|-------|---------------|--------------|-------------|-------------|-------|
| Q1 FY24 | 41.4 | +34% | 19.8 | — | 1.5 | — | Early launch |
| Q2 FY24 | 54.1 | +68% | 27.1 | — | 1.9 | — | Ramping |
| Q3 FY24 | 62.9 | +70% | 35.6 | — | 1.9 | — | Momentum |
| Q4 FY24 | 74.8 | +66% | 49.6 | — | 1.3 | — | Strong close |
| Q1 FY25 | 81.7 | +97% | 55.9 | +182% | 5.9 | — | Acceleration |
| Q2 FY25 | 114.4 | +112% | 71.9 | +165% | 19.6 | $0.13 | CSL milestone |
| Q3 FY25 | 164.9 | +162% | 90.9 | +155% | 51.7 | $0.59 | Big CSL milestone quarter |
| Q4 FY25 | 129.7 | +73% | 103.3 | +108% | 3.1 | $0.37 | Normalized; 908 PSFs (ATH) |
| **FY25** | **490.7** | **+110%** | **322.0** | **+144%** | **80.3** | **$0.91** | **First Non-GAAP profitable year** |

**FY26 Guidance:** "Meani

*…truncated*

# TVTX — Travere Therapeutics: Deep Dive Stock Analysis

> Date: 2026-04-02
> Analyst: muji (CMF_muji)
> Type: First coverage — stock analysis
> Market cap: ~$2.5B | P/S (TTM): 5.7x | Revenue: $490.7M FY25 (+110.3% YoY)
> Stock: ~$27.56 | 52-week: $12.91–$42.13 | Shares: 90.9M

---

## Links

- Q4 FY25 Earnings PR: BusinessWire Feb 19, 2026
- Scout brief: `briefs/TVTX_stock-analysis_2026-04-01/`
- Atlas baseline: `atlas/analyses/TVTX/TVTX_stock-analysis_2026-04.md`

---

## The Short Version

Here's the thing... TVTX isn't a typical muji company. It's not SaaS, it's not cybersecurity, it's not cloud infrastructure. It's a specialty pharma company. But the *framework* still applies — and when I apply it, what I see is a **platform story disguised as a single-drug stock**, trading at a valuation that would make any growth investor salivate.

FILSPARI is growing at +108% YoY (Q4), gross margins are 98%, the company just inflected to positive operating cash flow for the first time ever, and PSF count (the leading indicator) just hit an all-time high of 908. The stock trades at 5.7x trailing revenue on 110% growth. That's a PEG of 0.05. **DING DING DING.**

There's a massive binary catalyst in 11 days — FSGS PDUFA April 13. If approved, FILSPARI becomes the first and only approved therapy for FSGS, roughly doubling the addressable patient population with zero incremental field force cost. If rejected, the IgAN franchise alone still justifies current valuation.

**Tier: 1** (>75% growth, platform optionality, profitability inflection)

long TVTX — first coverage, sizing discussion below.

---

## Platform Assessment (muji's Layer)

IMHO this is where the market is fundamentally misunderstanding TVTX. Everyone looks at this as "a company with one drug." That's wrong. Let me explain.

### The Nephrology Platform

TVTX is building a **kidney disease platform**. The "platform" isn't software — it's the combination of:

1. **The field force (100+ nephrology specialist reps)** 

*…truncated*

# TVTX — Travere Therapeutics: Stock Analysis

> Date: 2026-04-02
> Analyst: Bert Hochfeld
> Market cap: ~$2.6B | Share price: ~$28.50 (est. Apr 2, 2026) | Shares: 90.9M
> FY ends: December (calendar year)
> Atlas baseline: Read and incorporated. I agree with the qualification gate, six-factor scoring, and scuttlebutt findings. My analysis adds explicit valuation discipline using EV/S cohort methodology, convertible debt term analysis, and GARP-spectrum positioning. I diverge from Atlas on the weight given to FSGS binary risk in position sizing.

---

**Summary:** I have not covered Travere Therapeutics in the newsletter, but applying my framework, TVTX presents one of the most compelling risk-reward profiles I have seen in commercial-stage biotech. FILSPARI, the company's first-in-class kidney drug, grew revenue 144% YoY to $322M in FY25 with 98% gross margins and brought the company to its first year of positive operating cash flow. The stock trades at a P/S of 5.3X on $490.7M of trailing revenue, which translates to a PEG of 0.05X — a number so low it makes the most discounted software names I follow look expensive by comparison. The FSGS PDUFA decision on April 13 is 11 days away and represents an asymmetric catalyst: approval would make FILSPARI the first and only drug approved for FSGS, roughly doubling the addressable patient population with no incremental field force investment. The convertible notes ($275M face, $31.87 conversion price, maturing March 2029) are currently out-of-the-money and redeemable by the company since March 2026. This is a GARP opportunity of the first order, tempered only by the binary nature of the FSGS decision and the transition from single-drug concentration to multi-product platform.

---

## Business Overview

Travere Therapeutics is a specialty pharmaceutical company focused on rare kidney and metabolic diseases. The business has two commercial products:

**FILSPARI (sparsentan)** is a once-daily oral dual endothelin and angiot

*…truncated*